Skip to content

Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial

Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029636
Enrollment
Unknown
Registered
2020-02-08
Start date
2020-02-09
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Case series:Conventional standardized treatment and vMIP atomized inhalation

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged >=18 years, gender unlimited, inpatient; 2) Patients with new coronavirus infection were confirmed: respiratory or blood samples were positive for 2019 ncov nucleic acid by real-time fluorescent RT-PCR, or respiratory or blood samples were highly homologous with known 2019 ncov gene sequencing; 3) According to the standard of "diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5)", the clinical types are common type or severe type; 4) The time interval between symptom onset and enrollment was within 7 days. The symptom onset was mainly based on fever. If there was no fever, coughing or other related symptoms could be used, such as fatigue, nasal obstruction, runny nose, chest distress, sore throat, muscle ache, diarrhea, etc; 5) Informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1) Known or suspected to be allergic to the components of vMIP. 2) Confirmed hepatitis B, C, AIDS and other viral infections. 3) Acute respiratory distress syndrome (ARDS) was found. 4) According to the judgment of the researchers, there are other conditions that are not suitable for the experiment. 5) Pregnant, lactating women or during the trial period and within 6 months after the end of the family planning. 6) Have participated in other clinical trials or are using experimental drugs within 12 weeks before administration.

Design outcomes

Primary

MeasureTime frame
2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;

Secondary

MeasureTime frame
Clearance rate and time of main symptoms (fever, fatigue, cough);immune indices;

Countries

China

Contacts

Public ContactHu bo, Li wei

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

hubo@mail.hust.edu.cn+86 13707114863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026